Dr Dionysis Papadatos-Pastos | London Lung Oncologist
I am a London based oncologist, specialist in the treatment of lung cancer, mesothelioma and thymic tumors.
Conditions treated
Comprehensive thoracic cancer treatment
Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of cases. It includes adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. NSCLC typically grows and spreads more slowly than small cell lung cancer. Early detection and treatment are crucial
Small Cell Lung Cancer
Small cell lung cancer (SCLC) is a fast-growing type of lung cancer that originates in the bronchi and quickly spreads to other parts of the body. It accounts for about 10-15% of all lung cancers. New treatments, including immunotherapy combined with chemotherapy, are showing promise in improving patient outcomes
Mesothelioma
Mesothelioma is a rare, aggressive cancer that develops in the mesothelium, the thin layer of tissue covering most internal organs, often linked to asbestos exposure1. New treatments, such as immunotherapy have been shown to improve survival rates and quality of life for patients
Thymic tumors
Thymic tumors are rare cancers originating in the thymus gland, located in the upper chest. They include thymomas, which grow slowly, and thymic carcinomas, which are more aggressive. New treatments, such as targeted therapy and immunotherapy, are being investigated to improve outcomes for patients with advanced thymic tumors
Testimonials
What Our Patients Are Saying
On meeting Dr Papadatos for the first time he recommended I stay on the immunotherapy treatment. I have since been undergoing the treatment every 6 weeks and so far I am responding well with very little side effects. Dr Papadatos explained everything fully to me and has a very reassuring, confidant manor. He seems like a very nice pleasant man who I fully trust. He listened to my questions and answered them thoroughly. If it was possible I would recommend Dr Papadatos to anyone needing the care of an oncologist.
As seen in iwantgreatcare
Dr Papadatos-Pastos Is the most amazing oncologist, he makes you feel you are in safe hands always, he listens to your questions and answers you in a way you can understand. He has been my oncologist for the past 3 years, and I trust him with my life. Couldn’t recommend him any higher.
As seen in iwantgreatcare
Dr Papadatos-Pastos is an excellent doctor. I found him very open, caring, gentle and warm. He made me feel positive and hopeful. Apart from being a skilled oncologist he made a great impact on me. Under his treatment I am doing very well.
I wish him all the best.
As seen in iwantgreatcare
Very pleased with the consultation. He took the time to answer all questions. I’d highly recommend.
As seen in topdoctors
Dr Dionysis Papadatos-Pastos gives useful explanation and satisfactory advise.
As seen in topdoctors
Why surgery should not be routinely used in patients with mesothelioma
The MARS2 trial (Mesothelioma and Radical Surgery 2) was designed to evaluate the effectiveness of...
Clinical trials
Clinical trials are crucial in advancing lung cancer treatment, offering patients access to cutting-edge therapies...
Immunotherapy in NSCLC
Immunotherapy has transformed the treatment landscape for non-small cell lung cancer (NSCLC), offering new hope,...
Advanced stage small cell lung cancer
Extensive-stage small cell lung cancer (SCLC) is a challenging diagnosis, as it indicates the cancer...
Early stage small cell lung cancer
The treatment of early-stage small cell lung cancer (SCLC) has traditionally involved a combination of...
Recent Advances in the Treatment of EGFR (common mutations)-Driven Non-Small Cell Lung Cancer (NSCLC)
Lung cancer is one of the most common and deadliest cancers worldwide, and about 85%...
Treatment of ROS1-Driven Lung Cancer: A Comprehensive Overview
Lung cancer remains one of the most common and lethal cancers worldwide, but advances in...
Targeted therapies in NSCLC
Targeted therapies have revolutionized the treatment of non-small cell lung cancer (NSCLC), offering more personalized...
Understanding ALK-Driven Non-Small Cell Lung Cancer (NSCLC)
Anaplastic Lymphoma Kinase (ALK)-driven non-small cell lung cancer (NSCLC) is a subtype of lung cancer...
Media
To intensify or not to intensify 1L treatment in EGFR-Mutated NSCLC?
Resources for physicians: Dr Papadatos-Pastos presentation on 1st line treatment for EGFR driven non small...
Dr Papadatos-Pastos in the Evening Standard (10 September 2024)
Hopeful horizons for lung cancer patients As seen in the Evening Standard newspaper on September...